Recombinant Human Ly6D Fc Chimera Protein, CF

Catalog #: 10169-L6 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10169-L6-050

Recombinant Human Ly6D Fc Chimera Protein Bioactivity

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Ly6D Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1-7.5 μg/mL.

Source

Human embryonic kidney cell, HEK293-derived human Ly6D protein

Human Ly6D (Leu21-Asn98) Accession # Q14210	GGGS	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

Q14210

N-terminal Sequence
Analysis

Leu21

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

35 kDa

SDS-PAGE

38-46 kDa, under reducing conditions

Product Datasheets

10169-L6

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10169-L6

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human Ly6D Fc Chimera (Catalog # 10169-L6) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1-7.5 μg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human Ly6D Fc Chimera (Catlog # 10169-L6) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 38-46 kDa and 80-90 kDa, respectively.

Reconstitution Calculator

Background: Ly6D

Ly6D (Lymphocyte antigen 6D), also known as E48 antigen, is a member of the lymphostromal cell membrane Ly6 protein superfamily (1, 2). There are at least twenty different human Ly6 proteins that have been identified, ranging from 11 to 36 kDa. These are classified as either secreted, or membrane-bound proteins which have the GPI-anchor signaling sequence. Included in the GPI-anchored cell surface glycoproteins are Ly6A-I and Ly6K (2-4). Human Ly6D is synthesized as a 128 amino acid (aa) protein that includes a 20 aa signal peptide, a 78 aa Ly6D chain, and a 30 aa propeptide. Within the main chain region, human Ly6D shares 64% and 58% aa sequence identity with mouse and rat Ly6D, respectively. Ly6D expression is significantly increased in bladder, brain and CNS, breast, head and neck, gastric, lung, ovarian, pancreatic, colorectal and kidney cancer than their counterpart normal tissues. High Ly6D expression is correlated with poor clinical outcome in brain and CNS, pancreatic, and colorectal, breast, colorectal, lung, gastric and ovarian cancer (4). LY6D is a progenitor marker that liaises intrinsically castration-resistant luminal cells and castration-resistant prostate tumor growth (5). LY6D is associated with an aggressive phenotype of ER-positive breast carcinoma, and these are potent markers for distant metastasis of ER-positive breast cancer patients (6).

References